Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging

Radiology

Volumn 264, Issue 3, 2012, Pages 670-678

  King, Valencia ^a   Goldfarb, Shari B ^a   Brooks, Jennifer D ^a   Sung, Janice S ^a   Nulsen, Benjamin F ^b   Jozefara, Jolanta E ^c   Pike, Malcolm C ^a   Dickler, Maura N ^a   Morris, Elizabeth A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EXEMESTANE; FLUOROURACIL; GADOLINIUM PENTETATE; LETROZOLE; METHOTREXATE; PACLITAXEL;

ADULT; AGE; AGED; ARTICLE; BACKGROUND PARENCHYMAL ENHANCEMENT; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVOR; CONTRAST ENHANCEMENT; FEMALE; FIBROGLANDULAR TISSUE; HUMAN; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGICAL PARAMETERS; POSTMENOPAUSE; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANDROSTADIENES; AROMATASE INHIBITORS; BREAST NEOPLASMS; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOPLASM STAGING; NITRILES; POSTMENOPAUSE; RETROSPECTIVE STUDIES; SUBTRACTION TECHNIQUE; TRIAZOLES;

EID: 84865408567     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.12112669     Document Type: Article

References (31)

1. Brennan S, Liberman L, Dershaw DD, Morris E. Breast MRI screening of women with a personal history of breast cancer. AJR Am J Roentgenol 2010;195(2):510-516.
2. Lee CH, Dershaw DD, Kopans D, et al. Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J Am Coll Radiol 2010;7(1):18-27.
3. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-62.
4. Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005;23(22):5138-5147.
5. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366(9484):455-462.
6. BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009;361(8):766-776.
7. Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B, Keshaviah A, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353(26):2747-2757.
8. Coates AS, Keshaviah A, Thürlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007;25(5):486-492.
9. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. Forbes JF, Cuzick J, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for earlystage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9(1):45-53.
10. Kuhl CK, Bieling HB, Gieseke J, et al. Healthy premenopausal breast parenchyma in dynamic contrast-enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency. Radiology 1997;203(1):137-144.
11. Müller-Schimpfle M, Ohmenhaüser K, Stoll P, Dietz K, Claussen CD. Menstrual cycle and age: influence on parenchymal contrast medium enhancement in MR imaging of the breast. Radiology 1997;203(1):145-149.
12. Hussain Z, Roberts N, Whitehouse GH, García-Fiñana M, Percy D. Estimation of breast volume and its variation during the menstrual cycle using MRI and stereology. Br J Radiol 1999;72(855):236-245.
13. Graham SJ, Stanchev PL, Lloyd-Smith JO, Bronskill MJ, Plewes DB. Changes in fibroglandular volume and water content of breast tissue during the menstrual cycle observed by MR imaging at 1.5 T. J Magn Reson Imaging 1995;5(6):695-701.
14. Delille J-P, Slanetz PJ, Yeh ED, Kopans DB, Halpern EF, Garrido L. Hormone replacement therapy in postmenopausal women: breast tissue perfusion determined with MR imaging-initial observations. Radiology 2005;235(1):36-41.
15. Harvey JA, Santen RJ, Petroni GR, et al. Histologic changes in the breast with menopausal hormone therapy use: correlation with breast density, estrogen receptor, progesterone receptor, and proliferation indices. Menopause 2008;15(1):67-73.
16. Pfleiderer SO, Sachse S, Sauner D, et al. Changes in magnetic resonance mammography due to hormone replacement therapy. Breast Cancer Res 2004;6(3):R232-R238.
17. Morris EA. Diagnostic breast MR imaging: current status and future directions. Radiol Clin North Am 2007;45(5):863-880.
18. King V, Kaplan JB, Pike MC, et al. Impact of tamoxifen on fibroglandular tissue, background parenchymal enhancement, and cysts on breast magnetic resonance imaging. Breast J (in press).
19. Eng-Wong J, Orzano-Birgani J, Chow CK, et al. Effect of raloxifene on mammographic density and breast magnetic resonance imaging in premenopausal women at increased risk for breast cancer. Cancer Epidemiol Biomarkers Prev 2008;17(7):1696-1701.
20. Oksa S, Parkkola R, Luukkaala T, MäenpääJ. Breast magnetic resonance imaging findings in women treated with toremifene for premenstrual mastalgia. Acta Radiol 2009;50(9):984-989.
21. King V, Brooks JD, Bernstein JL, Reiner AS, Pike MC, Morris EA. Background parenchymal enhancement at breast MR imaging and breast cancer risk. Radiology 2011;260(1):50-60.
22. Mousa NA, Eiada R, Crystal P, Nayot D, Casper RF. The effect of acute aromatase inhibition on breast parenchymal enhancement in magnetic resonance imaging: a prospective pilot clinical trial. Menopause 2012;19(4):420-425.
23. Yue W, Wang JP, Hamilton CJ, Demers LM, Santen RJ. In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res 1998;58(5):927-932.
24. Lønning PE, Haynes BP, Straume AH, et al. Exploring breast cancer estrogen disposition: the basis for endocrine manipulation. Clin Cancer Res 2011;17(15):4948-4958.
25. Prowell TM, Blackford AL, Byrne C, et al. Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole. Cancer Prev Res (Phila) 2011;4(12):1993-2001.
26. Cigler T, Tu D, Yaffe MJ, et al. A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women. Breast Cancer Res Treat 2010;120(2):427-435.
27. Vachon CM, Ingle JN, Suman VJ, et al. Pilot study of the impact of letrozole vs. placebo on breast density in women completing 5 years of tamoxifen. Breast 2007;16(2):204-210.
28. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003;95(1):30-37.
29. Mousa NA, Crystal P, Wolfman WL, Bedaiwy MA, Casper RF. Aromatase inhibitors and mammographic breast density in postmenopausal women receiving hormone therapy. Menopause 2008;15(5):875-884.
30. Brisson J, Brisson B, Coté G, Maunsell E, Bérubé S, Robert J. Tamoxifen and mammographic breast densities. Cancer Epidemiol Biomarkers Prev 2000;9(9):911-915.
31. Cuzick J, Warwick J, Pinney E, Warren RML, Duffy SW. Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst 2004;96(8):621-628.